News
It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...
Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S ...
Over his eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company said. However, the shares ...
Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...
A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first quarter 20245 investor ...
Novo Nordisk A/S is replacing Chief Executive Officer Lars Fruergaard Jorgensen as the drugmaker wrestles with increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results